blog

Foreign modelling agent reactions in wound care

Thomas Serena, MD — Wed, 03 Jun 2026 22:16:16 GMT

What is foreign modelling agent reaction and why it matters in wound care

Foreign modelling agent reaction (FMAR) is a chronic inflammatory and granulomatous response to injected, non‑biodegradable substances used for cosmetic body contouring, such as mineral oil, silicone, or acrylates. It can present years after injection with painful induration, ulceration, and systemic complications, and often reaches specialized wound centers late.

FMAR has been described as an emerging epidemic in parts of Latin America, with case series from Mexico and Colombia reporting hundreds of affected patients over a decade and some centers seeing dozens of new cases per week. Typical injectors are non‑medical personnel using industrial‑grade oils or mixed substances for buttock, breast, or leg augmentation, frequently in women and in men who have sex with men.

For wound clinicians, FMAR matters because it mimics more familiar entities—infected pressure injuries, vasculitis, panniculitis, even malignancy—yet standard local care alone rarely controls the disease. The injected material migrates through subcutaneous planes and lymphatics, driving persistent granulomatous inflammation, recurrent infections, and difficult‑to‑heal ulcers.

Beyond local tissue damage, FMAR can trigger autoimmune/inflammatory phenomena and life‑threatening events such as fat‑like embolism and acute lung injury, described in several case reports and series available through open‑access literature (for example, Martínez‑Villarreal et al., 2016). Understanding this syndrome allows wound teams to recognise red flags early, avoid futile interventions, and route patients into multidisciplinary care pathways.

Recognising FMAR at the bedside: history, signs, and investigations

Foreign modelling agent reaction should be suspected in any patient with chronic indurated plaques, nodules, or ulcers in typical augmentation sites—especially buttocks, thighs, legs, breasts, or genitalia—when the clinical course seems out of proportion to usual etiologies and standard therapy.

History is critical. Patients may not volunteer cosmetic injections, particularly if procedures were illicit, low‑cost, or performed abroad. Ask neutrally about “any injections or fillers for shaping this area,” including “vitamins,” “collagen,” or “biopolymers.” Latency from injection to symptoms can range from weeks to over 10 years, so take a long timeline.

Common local findings include board‑like induration, erythema, alternating hyper‑ and hypopigmentation, nodules, and draining sinuses with oily or purulent material. Ulcers often have undermined borders over a woody, sclerotic base. Lesions can extend far beyond the original injection site due to gravitational or lymphatic migration of the material.

Basic workup starts with photography and careful mapping of all affected areas. Laboratory tests typically show elevated inflammatory markers (CRP, ESR) and may reveal leukocytosis or autoantibodies in some patients. Swab or tissue cultures help identify superimposed bacterial or atypical mycobacterial infection, which was documented in a minority of cases in large series.

Imaging refines the diagnosis and extent. MRI, when available, is highly informative: it demonstrates the volume, depth, and pattern of the foreign material and associated inflammation, guiding surgical planning. Where MRI access is limited, ultrasound can still reveal increased echogenicity and depth of subcutaneous involvement. A deep skin or soft‑tissue biopsy remains important to confirm granulomatous foreign body reaction and exclude malignancy.

Practical management of FMAR ulcers: multidisciplinary and preventive approaches

Foreign modelling agent reaction ulcers require a dual approach: meticulous wound bed preparation and strategic control of the underlying inflammatory process. Without addressing both, recurrence and chronicity are the rule, not the exception.

At the wound level, standard principles apply: identify and debride non‑viable tissue using a modality tailored to pain, vascular status, and infection risk (surgical, mechanical, enzymatic, or biologic). Case series describe successful use of negative pressure wound therapy for large, exudative FMAR ulcers to promote granulation and reduce bioburden over weeks to months.

Topical dressings should maintain moisture balance while addressing contamination. Silver‑impregnated foams, polyhexanide gauze, or povidone‑iodine can be useful during high‑bioburden phases, followed by less cytotoxic options such as calcium alginate or modern super‑absorbent dressings as exudate decreases. Compression may be added cautiously on the lower extremities if arterial supply is adequate and pain is controlled.

Because injected material is diffusely intermixed with normal tissue, complete excision is often impossible. However, targeted surgical resection of dominant masses or chronically infected pockets—with flap or graft reconstruction—has improved outcomes in selected patients, especially for mammary or genital FMAR reported in reconstructive surgery literature (two‑stage reconstructions being one example).

Equally important is assembling a multidisciplinary team: dermatology, plastic or general surgery, infectious diseases, rheumatology, mental health, and rehabilitation. Patients frequently endure years of pain, disfigurement, and stigma; clear expectation‑setting—that disease control, not cure, is often the goal—can prevent disengagement from care when rapid improvement does not occur.

Systemic risks of FMAR and when to escalate care

Foreign modelling agent reaction is not just a skin problem; it can involve lungs, liver, kidneys, musculoskeletal system, and the immune axis. Wound clinicians must recognise when a seemingly localized ulcer represents a systemic hazard requiring urgent escalation.

Red flags include unexplained dyspnea, cough, or hypoxia in any patient with a history of large‑volume injections. Case reports describe acute and delayed “silicone embolism” or fat‑like embolic syndromes after gluteal or breast injections, sometimes triggered by manipulation or incision and drainage procedures. Progressive respiratory symptoms in this context warrant immediate emergency referral, imaging, and specialist input.

Other concerning systemic features are persistent fevers, weight loss, arthralgias, Raynaud‑like episodes, or laboratory evidence of multi‑organ involvement (rising creatinine, abnormal liver function tests, cytopenias). Some FMAR patients meet proposed criteria for autoimmune/inflammatory syndromes induced by adjuvants, with autoantibody positivity and hypergammaglobulinemia reported in observational cohorts.

When systemic involvement is suspected, collaboration with rheumatology and internal medicine is essential. Published protocols from high‑volume Latin American centers describe stepwise use of oral corticosteroids (such as deflazacort) followed by immunomodulators including colchicine, azathioprine, hydroxychloroquine, or, in refractory cases, cyclophosphamide or TNF‑alpha inhibitors. These regimens require close monitoring and are generally beyond the remit of stand‑alone wound clinics.

For front‑line staff, the key actions are early recognition, thorough documentation, and timely referral rather than attempting to manage complex systemic FMAR in isolation.

Communicating with patients about illicit fillers and long‑term prognosis

Foreign modelling agent reaction carries heavy psychological and social burdens. Many patients feel shame about having sought low‑cost cosmetic enhancement, especially if done by unlicensed providers or outside the formal health system. Sensitive, non‑judgmental communication from the wound team is crucial.

Begin by validating the patient’s experience—acknowledging their pain, disfigurement, and fear of further loss of function or attractiveness. Clearly explain that the reaction is caused by the body’s response to the injected material, not by poor personal hygiene or non‑adherence. Use plain language to describe chronic inflammation and scarring, and why symptoms may flare episodically even with treatment.

Set realistic expectations about prognosis. Data from long‑term series show median latency of several years to symptom onset and protracted courses of care, often over multiple years. Complete removal of all material is rarely achievable; instead, goals include pain control, ulcer closure where possible, infection prevention, and maintaining mobility and body image.

It is also important to explore mental health impacts. Depression, anxiety, and body dysmorphic concerns are common but under‑reported. Establish relationships with behavioral health colleagues or community resources experienced in appearance‑related distress. When discussing reconstruction, emphasize functional priorities (sitting, walking, intimacy without pain) rather than purely aesthetic perfection.

Finally, encourage patients to avoid further injections or “touch‑ups,” which some may consider to camouflage deformities. Additional unregulated fillers almost always worsen disease activity and complicate future surgical options.

Building protocols to identify and track FMAR in wound clinics

Foreign modelling agent reaction will likely remain under‑recognized unless wound services deliberately screen for it. Simple clinic‑level protocols can improve detection, documentation, and long‑term outcomes while generating data for quality improvement and research.

Start with standardized intake questions for all patients presenting with ulcers or chronic induration in high‑risk anatomical sites. Include prompts about cosmetic or body‑contouring injections, location and date, who performed the procedure, and what substance was reported. Normalizing these questions—asking everyone—reduces stigma and missed disclosures.

Next, create a structured documentation template capturing typical FMAR features: distribution of plaques/ulcers, degree of induration, color changes, presence of nodules or fistulas, pain scores, systemic symptoms, and prior interventions. Consistent photography at each visit allows objective comparison and can support surgical planning or external consultations.

Where possible, define referral thresholds to dermatology, surgery, rheumatology, and infectious disease based on red‑flag criteria (e.g., rapidly progressive induration, recurrent systemic infections, respiratory complaints). Embedding these triggers into electronic records or checklists helps frontline nurses and APPs escalate cases promptly.

Finally, consider participating in registries or institutional audits of FMAR cases, recording substances (when known), latency, complications, and outcomes. Published series from high‑volume centers demonstrate how such datasets can inform staging systems and treatment algorithms. Even small numbers from individual clinics add to the global understanding of this preventable, high‑impact cause of chronic wounds.

Clinical Trials: Diabetic Foot Ulcer Treatments

Thomas Serena, MD — Wed, 27 Aug 2025 21:08:38 GMT

Exploring innovative treatments for non-healing diabetic foot ulcers through cutting-edge randomized controlled trials

The Growing Burden of Diabetic Foot Ulcers

Diabetic foot ulcers (DFUs) represent a significant global health challenge, affecting millions of individuals with diabetes, particularly those with type 2 diabetes mellitus (T2DM). These ulcers often result from a combination of peripheral neuropathy, peripheral arterial disease, and structural foot deformities. These conditions are frequently exacerbated by factors such as inappropriate footwear and unrecognized minor trauma.

Despite standardized management strategies, including serial sharp debridement, biomechanical offloading, and infection control, the healing outcomes for DFUs remain suboptimal. The financial burden of DFU treatment is significant, with healthcare expenditures in the United States alone exceeding $38 million annually. Furthermore, individuals from low-income or underserved populations often face substantial barriers to accessing advanced wound care services.

Introduction to PURION-Processed Lyophilized Human Amnion/Chorion Membrane

PURION-processed lyophilized human amnion/chorion membrane (ppLHACM) products, such as EPIEFFECT and EPIXPRESS, have shown significant promise in the treatment of chronic, non-healing wounds. These biologically derived allografts are known for their anti-inflammatory, antimicrobial, antifibrotic, and pro-epithelialization properties, making them a compelling therapeutic option for DFUs.

The processing method preserves the extracellular matrix (ECM) components and sterilizes the graft, ensuring that each layer is adequately cleansed before forming the tri-layer configuration. This meticulous process enhances the regenerative potential of these products, supporting tissue regeneration and promoting wound healing.

Modified Platform Trial Design: A Game Changer in Wound Care Research

The novel modified platform trial design employed in this study represents a significant advancement in wound care research. Unlike conventional randomized controlled trials, which are typically limited in scope and time, platform trials incorporate adaptive features that allow for the addition or discontinuation of study arms based on pre-defined interim analyses.

This flexibility supports real-time decision-making and improves trial efficiency by sharing infrastructure, control arms, and statistical frameworks across multiple investigational products. The adaptive platform structure permits the introduction of additional ppLHACM or advanced wound care products through protocol amendments, ensuring that the trial remains scientifically rigorous and clinically relevant as new evidence and technologies emerge.

Study Objectives and Methods

The primary objective of this study is to evaluate the efficacy of ppLHACM products in achieving complete wound closure within 12 weeks when used in conjunction with standard of care (SOC) compared to SOC alone. Secondary objectives include determining the time to closure, percentage area reduction, the frequency and nature of adverse events, and quality of life assessments.

The trial is a multicenter, prospective, randomized controlled trial utilizing a modified platform design. Patients with non-healing DFUs are randomized into three groups: SOC alone or SOC plus one of two ppLHACM products. Exploratory objectives include assessing offloading compliance, bacterial load, host protease activity, and continuous glucose monitoring data. The study is anticipated to require 24 months to complete, with up to 30 SerenaGroup or affiliated sites included.

Potential Impact on Clinical Practice and Future Research

This trial is expected to provide high-quality efficacy data on ppLHACM products, contributing to evidence-based practice in DFU management. The integration of continuous glucose monitoring (CGM) technology represents an innovative advancement, allowing for real-time, dynamic tracking of interstitial glucose levels, which can provide a more granular understanding of glycemic control and its impact on wound healing.

The successful implementation of this trial may serve as a model for future investigations in regenerative medicine, supporting the evolution of more responsive, efficient, and evidence-based approaches to chronic wound management. Future research may expand on this platform to include additional product classes, explore subgroup analyses based on wound characteristics or patient risk profiles, and incorporate emerging digital technologies for wound monitoring.

Hyperbaric Chamber Therapy: Benefits for Wound Healing

Meriann Kelley-DeTeso — Thu, 24 Jul 2025 18:10:50 GMT

Discover how hyperbaric chamber therapy can accelerate wound healing and improve overall patient outcomes.

How Hyperbaric Oxygen Therapy Promotes Wound Healing

Hyperbaric Oxygen Therapy (HBOT) works by increasing the amount of oxygen your blood can carry. Under high pressure, oxygen dissolves more effectively into the body's fluids, including plasma, lymph, and cerebrospinal fluid. This enhanced oxygen delivery accelerates the body's natural healing processes and helps fight off infections.

Specifically, for wound healing, HBOT stimulates the growth of new blood vessels, enhances the effectiveness of white blood cells in fighting infection, and reduces inflammation and swelling. This therapy is particularly effective for patients with chronic wounds, such as diabetic ulcers, where traditional methods have failed.

Common Conditions Treated with Hyperbaric Chamber Therapy

Hyperbaric chamber therapy is not limited to wound healing; it is also used to treat a variety of medical conditions. These include diabetic foot ulcers, radiation injuries, decompression sickness, and certain types of infections like necrotizing fasciitis. Additionally, HBOT is beneficial for patients suffering from carbon monoxide poisoning, crush injuries, and skin grafts or flaps that are at risk of failing.

The therapy is also being studied for its potential benefits in treating traumatic brain injuries, post-stroke recovery, and even certain neurological conditions. The broad applicability of HBOT makes it a versatile treatment option in the medical field.

How to Access Hyperbaric Chamber Therapy

Accessing hyperbaric chamber therapy typically begins with a consultation from a healthcare provider who specializes in wound care or hyperbaric medicine. They will assess your specific medical condition and determine if HBOT is a suitable treatment option for you.

Once deemed appropriate, you will be referred to a facility equipped with hyperbaric chambers. These facilities are often part of hospitals or specialized clinics. It's essential to follow all pre-treatment guidelines provided by your healthcare team, such as avoiding certain medications or foods before undergoing therapy.

Managing Bacterial Load in Wounds with Moleculight

Gregory Bohn, MD — Tue, 01 Jul 2025 23:03:04 GMT

Discover how Moleculight technology is revolutionizing wound care by providing real-time visualization of bacterial load, leading to better patient outcomes.

The Importance of Managing Bacterial Load in Wound Care

Effective wound care management is crucial for preventing infections and promoting healing. Bacterial load in wounds can lead to complications such as delayed healing, increased pain, and even systemic infections. Understanding and controlling the bacterial environment in a wound is essential for optimal patient outcomes.

Healthcare providers need reliable tools to assess bacterial presence accurately. Traditional methods, such as swab cultures, can be time-consuming and may not always provide a clear picture of the bacterial load. This is where advanced technologies like Moleculight come into play, offering real-time visualization and enabling more informed clinical decisions.

How Moleculight Technology Works

Moleculight technology uses fluorescence imaging to detect and visualize bacteria in wounds. The device emits a specific wavelength of light that causes certain bacteria to fluoresce, making them visible to the naked eye. This real-time imaging allows clinicians to see areas with high bacterial load and make immediate adjustments to treatment strategies.

The process is non-invasive and can be performed quickly at the patient's bedside. The Moleculight device captures images, which are then analyzed to identify areas of concern. This allows for more targeted and effective wound care interventions, potentially reducing the need for antibiotics and other treatments.

Benefits of Using Moleculight for Wound Assessment

One of the primary benefits of using Moleculight technology is its ability to provide immediate, actionable information. Clinicians can see the exact location and extent of bacterial presence, allowing for more precise debridement and cleaning of wounds. This targeted approach can improve healing times and reduce the risk of infection.

Additionally, Moleculight helps in monitoring the effectiveness of treatments over time. By comparing images taken at different stages of care, healthcare providers can assess whether a wound is responding to treatment or if adjustments are needed. This ongoing assessment can lead to better overall patient outcomes and more efficient use of medical resources.

Future Prospects: Innovations in Wound Care with Moleculight

The future of wound care looks promising with innovations like Moleculight leading the way. As technology continues to advance, we can expect even more sophisticated tools for assessing and managing wounds. Future developments may include enhanced imaging capabilities, integration with electronic health records, and improved algorithms for analyzing bacterial loads.

Research is ongoing to expand the applications of Moleculight technology, potentially making it a standard tool in wound care across various healthcare settings. By staying at the forefront of these innovations, healthcare providers can ensure they are delivering the best possible care to their patients.